MedTrace Logo

KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children

NCT02646839 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-05-04

No results posted yet for this study

Summary

This is a phase II, open-label, non-randomized, prospective study of haploidentical transplantation using KIR-favorable donors for children with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT). The relationship of KIR2DL1 polymorphisms to survival in children with these diseases undergoing any approach to allogeneic HCT during the study time frame will also be determined.

Conditions

Interventions

DEVICE

CliniMacs TCR alpha-beta-Biotin system

Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells

Sponsors & Collaborators

  • University of California, San Francisco

    collaborator OTHER

  • Children's Hospital of Philadelphia

    collaborator OTHER

  • Medical College of Wisconsin

    collaborator OTHER

  • Ann & Robert H Lurie Children's Hospital of Chicago

    collaborator OTHER

  • New York Medical College

    collaborator OTHER

  • UCSF Benioff Children's Hospital Oakland

    collaborator OTHER

  • Vanderbilt University

    collaborator OTHER

  • Rady Children's Hospital, San Diego

    collaborator OTHER

  • Michael Pulsipher

    lead OTHER

Principal Investigators

  • Michael Pulsipher, MD · Children's Hospital Los Angeles

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2025-11-30
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02646839 on ClinicalTrials.gov